drugset / Trial / NCT05193370

Angiotensin II vs. Vasopressin in Septic Shock

NCT05193370

RandomizedParallel-groupOpen-labelTreatment

Summary

This will be a randomized controlled unblinded pragmatic single-center pilot trial of the use of vasopressin vs. angiotensin II as a second-line vasopressor in patients with septic shock and persistent hypotension despite moderate-to-high doses of norepinephrine.

Timeline

Start
2022-01-03
Primary completion
2022-11-30
Completion
2022-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide 20 unknown
Comparator Vasopressin Peptide 0.04 unknown